Almotriptan use in specific populations: Difference between revisions
Jump to navigation
Jump to search
(Created page with "__NOTOC__ {{Almotriptan}} {{CMG}}; {{AE}} {{PB}} ==Use in Specific Populations== ==References== {{Reflist|2}} Category:AntiMigaraineDrugs Category:Drugs") |
No edit summary |
||
| Line 5: | Line 5: | ||
==Use in Specific Populations== | ==Use in Specific Populations== | ||
* Pregnancy: based on animal data, may cause fetal harm | |||
* Nursing mothers: use Almotriptan with caution | |||
* Pediatric use: Almotriptan has not been studied in children under 12 years | |||
* Geriatric use: insufficient safety and efficacy data; use with caution, usually starting with the 6.25 mg dose | |||
* Hepatic impairment: use single 6.25 mg tablet as a starting dose; maximum daily dose 12.5 mg | |||
* Severe renal impairment: use single 6.25 mg tablet as a starting dose; maximum daily dose 12.5 mg | |||
==References== | ==References== | ||
| Line 12: | Line 16: | ||
{{Reflist|2}} | {{Reflist|2}} | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
Revision as of 02:13, 5 February 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Pratik Bahekar, MBBS [2]
Use in Specific Populations
- Pregnancy: based on animal data, may cause fetal harm
- Nursing mothers: use Almotriptan with caution
- Pediatric use: Almotriptan has not been studied in children under 12 years
- Geriatric use: insufficient safety and efficacy data; use with caution, usually starting with the 6.25 mg dose
- Hepatic impairment: use single 6.25 mg tablet as a starting dose; maximum daily dose 12.5 mg
- Severe renal impairment: use single 6.25 mg tablet as a starting dose; maximum daily dose 12.5 mg